Inhibiting p47phox is a rational therapeutic strategy to reduce oxidative stress for diseases where excessive ROS generation drives pathology, including cardiovascular disease, RA, neurodegeneration, metabolic disorders, and cancer. The gene discussed is NCF1; the disease is metabolic disease.